A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Walter, Harriet S., Rule, Simon A., Dyer, Martin J. S., Karlin, Lionel, Jones, Ceri, Cazin, Bruno, Quittet, Philippe, Shah, Nimish, Hutchinson, Claire V., Honda, Hideyuki, Duffy, Kevin, Birkett, Joseph, Jamieson, Virginia, Courtenay-Luck, Nigel, Yoshizawa, Toshio, Sharpe, John, Ohno, Tomoya, Abe, Shinichiro, Nishimura, Akihisa, Cartron, Guillaume, Morschhauser, Franck, Fegan, Christopher, Salles, Gilles
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2016
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4731845/
https://ncbi.nlm.nih.gov/pubmed/26542378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-08-664086
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi